AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21068104
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who restarted treatment during the year of DAS increase.
Trial: 8428895
Drug: quazepam 15
RxNorm normalized name: quazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quazepam 15 mg
Trial: 23991629
Drug: CSII with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII with metformin
Trial: 16511428
Drug: DNA prime,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA prime, recombinant fowlpox virus boost vaccine (1 mg pHIS-HIV-B at weeks 0 and 4, 5 x 10^7 pfu rFPV-HIV-B at week 8)
Trial: 8768868
Drug: CPA‐100 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA‐100 (100 mg/day) + TE (100 mg/week)
Trial: 8768868
Drug: CPA‐50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPA‐50 (50 mg/day) + TE (100 mg/week)
Trial: 8768868
Drug: TE (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TE (100 mg/week) alone
Trial: 1881954
Drug: Pulsed electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsed electrical stimulation (30 minutes, twice daily, pulse frequency of 128 pps, peak amplitude of 29.2 mA) for chronic dermal ulcers.
Trial: 1881954
Drug: Sham electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham electrical stimulation (same protocol as treatment group).
Trial: 3106459
Drug: GHRH 1‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH 1‐40 (1 microgram/Kg bw) iv at time 0 plus TRH (6 micrograms/min) infusion between ‐30 and +120 min
Trial: 3106459
Drug: TRH (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH (6 micrograms/min) infusion between ‐30 and +120 min
Trial: 30279333
Drug: Whole milk
RxNorm normalized name: Calcium fortified whole milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole milk supplementation (250 mL/day for four weeks)
Trial: 26689520
Drug: Peritubal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritubal analgesic infiltration with 10mL of bupivacaine
Trial: 18471347
Drug: Vildagliptin/metformin (50/1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet after a high-fat meal
Trial: 10686266
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) at 90% power of the motor threshold, stimulation frequency of 10 Hz for either 2 sec or 6 sec for 20 trains, treated for up to 20 treatment days.
Trial: 10686266
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) performed according to standard protocols.
Trial: 8336746
Drug: Combined out‐patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined out‐patient therapy program (physical exercise, dietary counseling, psychological support)
Trial: 3511478
Drug: True ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: True ultrasound (US) therapy
Trial: 3511478
Drug: Sham ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ultrasound (US) therapy
Trial: 31865815
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of botulinum toxin
Trial: 31721257
Drug: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHEN/TPM‐ER (3.75 mg/23 mg-15 mg/92 mg)
Trial: 18374841
Drug: Haloperidol (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1-4 mg per day)
Trial: 18374841
Drug: Amisulpride (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (200-800 mg per day)
Trial: 18374841
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg per day)
Trial: 18374841
Drug: Quetiapine (200-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (200-750 mg per day)
Trial: 18374841
Drug: Ziprasidone (40-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (40-160 mg per day)
Trial: 16326171
Drug: EGG diet
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGG diet (640 mg/d cholesterol)
Trial: 16326171
Drug: Placebo diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo diet (0 mg/d cholesterol)
Trial: 8237930
Drug: Concurrent illnesses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent illnesses
Trial: 30916001
Drug: Intraoperative oliguria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative oliguria (urinary output <0.5 ml kg‐1 h‐1)
Trial: 30916001
Drug: Intraoperative oliguria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative oliguria (urinary output <0.3 ml kg‐1 h‐1)
Trial: 26070528
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with lercanidipine (LER, 10-20mg)
Trial: 26070528
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with hydrochlorothiazide (HCT, 12.5-25mg)
Trial: 25956055
Drug: Interactive home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive home-based training delivered through the internet for 30 min daily for 20 weeks
Trial: 19101456
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B virus (HBV) control vaccine
Trial: 10715924
Drug: Continued aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continued aspirin therapy (100 mg daily)
Trial: 10715924
Drug: Stopped aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stopped aspirin therapy (1 week before procedure)
Trial: 1584314
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment at 300 U/kg body weight i.v. once a week for 3 months
Trial: 1584314
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) treatment and Control group
Trial: 3156621
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamethasone given pre- and post-operatively
Trial: 29727404
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg·kg)
Trial: 29727404
Drug: p-Synephrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-Synephrine (3 mg·kg)
Trial: 29727404
Drug: p-Synephrine +
RxNorm normalized name: synephrine
DrugBank: Synephrine (DB09203)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-Synephrine + Caffeine (3 mg·kg each)
Trial: 24456716
Drug: Lutonix DCB
RxNorm normalized name: DCB
DrugBank: Dichlorobenzene (DB14046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutonix DCB (2 μg/mm² paclitaxel)
Trial: 15868230
Drug: No anti-adhesion
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-adhesion treatment (control)
Trial: 11932569
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g.kg‐1 body mass)
Trial: 9798800
Drug: UDCA 20
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 20 mg/kg/day
Trial: 9128317
Drug: Bismuth-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based triple therapy (BTM): bismuth subnitrate 75 mg q.i.d., oxytetracycline 500 mg q.i.d., metronidazole 400 mg b.i.d. for 14 days
Trial: 9128317
Drug: Omeprazole-based triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based triple therapy (OAM): omeprazole 20 mg b.i.d., amoxicillin 750 mg b.i.d., metronidazole 400 mg b.i.d. for 14 days
Trial: 9128317
Drug: Bismuth-based triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-based triple therapy (BTM) in nonrandomized group with metronidazole-resistant strains
Trial: 9128317
Drug: Omeprazole-based triple
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-based triple therapy (OAM) in nonrandomized group with metronidazole-resistant strains
Trial: 7054901
Drug: Limb-sparing surgery
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limb-sparing surgery plus radiation therapy plus chemotherapy
Trial: 7054901
Drug: Amputation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amputation plus chemotherapy
Trial: 30650266
Drug: Fusidic Acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic Acid Cream (FAC) alone for mild acne (39 cases)
Trial: 30650266
Drug: Fusidic Acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic Acid Cream (FAC) combined with minocycline hydrochloride for severe acne (64 cases)
Trial: 30650266
Drug: Longzhu Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longzhu Ointment (LO) alone for mild acne (27 cases)
Trial: 30650266
Drug: Longzhu Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longzhu Ointment (LO) combined with minocycline hydrochloride for severe acne (56 cases)
Trial: 30650266
Drug: Fusidic Acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic Acid Cream (FAC)
Trial: 30650266
Drug: Longzhu Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longzhu Ointment (LO)
Trial: 30650266
Drug: Fusidic Acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic Acid Cream (FAC) and Longzhu Ointment (LO)
Trial: 21116645
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 45% ethanol and 18% 1-propanol with skin protecting ingredients (Softa-Man®)
Trial: 21116645
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (with and without additives)
Trial: 11506402
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) 2.0 g/kg given over one to two days
Trial: 11506402
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone tapering from 60 mg to 10 mg daily over six weeks
Trial: 9420037
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 250 mg
Trial: 9420037
Drug: Rifampin (RIF)
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (RIF) 600 mg
Trial: 9420037
Drug: Pyrazinamide (PZA)
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide (PZA) 1500 mg
Trial: 8493625
Drug: BRL 38227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 38227 (0.125, 0.25, and 0.5 mg)
Trial: 8493625
Drug: BRL 38227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 38227 (0.125 and 0.5 mg)
Trial: 8493625
Drug: BRL 38227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRL 38227 (0.5 mg)
Trial: 3104624
Drug: Praziquantel at
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel at a dose of 40 mg kg‐1
Trial: 3104624
Drug: Metrifonate at
RxNorm normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate at 10 mg kg‐1 (three fortnightly doses)
Trial: 3104624
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of metrifonate
Trial: 3104624
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metrifonate (10 mg kg‐1) and niridazole (25 mg kg‐1)
Trial: 3104624
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of praziquantel
Trial: 3104624
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metrifonate (10 mg kg‐1) and praziquantel (10 mg kg‐1)
Trial: 27923057
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified cereal supplement (FG)
Trial: 27923057
Drug: Meat-based complementary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meat-based complementary food (MG)
Trial: 27923057
Drug: Local cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local cereal supplement (LG)
Trial: 24462043
Drug: 100 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g/d of white fish (Namibia hake) with advice on a healthy diet
Trial: 20470283
Drug: Ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 5 mg daily for 2 months
Trial: 18331436
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (6 g/day containing 160 mg of eicosapentaenic acid and 100 mg of docosahexaenoic acid)
Trial: 14696018
Drug: Milnacipran 50
RxNorm normalized name: milnacipran 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 50 mg twice a day plus pindolol 2.5 mg three times a day
Trial: 14696018
Drug: Milnacipran 50
RxNorm normalized name: milnacipran 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran 50 mg twice a day plus placebo three times a day
Trial: 8601365
Drug: ibuprofen, 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen, 1600 mg/day
Trial: 1987534
Drug: 12% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% sucrose solution (2 mL) prior to blood collection
Trial: 6344181
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sustained release tablet containing norephedrine
Trial: 25100891
Drug: Electromagnetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromagnetic therapy (administered once a day for 1 hour for 8 weeks)
Trial: 14668578
Drug: Ticlopidine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine 500 mg twice daily
Trial: 11772700
Drug: Fluoxetine (N=24)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (N=24)
Trial: 26520216
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) in combination with Treatment as Usual (TAU)
Trial: 21315215
Drug: 3,000-U anti-Xa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000-U anti-Xa certoparin once daily
Trial: 18996639
Drug: Vitamin B
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B therapy (group B)
Trial: 16427339
Drug: High-dose pulse-spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pulse-spray thrombolysis (rt-PA, 15 mg/h for 2h)
Trial: 16427339
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion (rt-PA, 0.5 mg/h for 48 h)
Trial: 16427339
Drug: High-dose pulse-spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pulse-spray thrombolysis
Trial: 19945274
Drug: Low-dose infusion
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose infusion
Trial: 10718829
Drug: Diluted ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diluted ethanol (0.45 g ethanol/kg b.w.)
Trial: 10718829
Drug: Water (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (150 ml doses)
Trial: 1401653
Drug: Terfenadine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (300 mg)
Trial: 17390144
Drug: Balsalazide 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balsalazide 2.25 g daily for 10 days every month plus VSL#3 450 billions/day for 15 days every month
Trial: 15668539
Drug: fosamprenavir/RTV 700/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fosamprenavir/RTV 700/100 mg (arm B)
Trial: 15668539
Drug: LPV/RTV/fosamprenavir 400/100/700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/RTV/fosamprenavir 400/100/700 mg (arm C)
Trial: 15668539
Drug: LPV/RTV 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPV/RTV 400/100 mg (arm A)
Trial: 7636540
Drug: Dexverapamil (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexverapamil (escalated from 240 to 1,200 mg/m2/d) combined with EPOCH chemotherapy
Trial: 7636540
Drug: EPOCH chemotherapy
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPOCH chemotherapy alone
Trial: 345414
Drug: Methylated analogues
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylated analogues of prostaglandin E2 administered orally
Trial: 26429629
Drug: ORALMENT (L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORALMENT (L-menthol oral administration)
Trial: 26429629
Drug: SKINMENT (L-menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKINMENT (L-menthol skin administration)
Trial: 26429629
Drug: ORALCON (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORALCON (control for oral administration)
Trial: 26429629
Drug: SKINCON (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKINCON (control for skin administration)
Trial: 23883424
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL syringe
Trial: 23883424
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL syringe
Trial: 23883424
Drug: 60 mL
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mL syringe
Trial: 16643233
Drug: 1.5 mg/ml
RxNorm normalized name: thymol 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/ml levobupivacaine via CEI (15 mg/h)
Trial: 16643233
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml levobupivacaine via CEI (15 mg/h)
Trial: 16643233
Drug: 1.5 mg/ml
RxNorm normalized name: thymol 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Trial: 16643233
Drug: 5 mg/ml
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/ml levobupivacaine via PCEA (5 mg bolus, 20 min lockout)
Trial: 15292626
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of cognitive-behavioral therapy and ethyl loflazepate (2 mg daily) for 6 weeks
Trial: 15292626
Drug: Antianxiety agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antianxiety agent only (ethyl loflazepate) for 6 weeks
Trial: 15292626
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only group
Trial: 11321637
Drug: Self-study of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-study of chess positions (500 positions over several months, 15-30 minutes daily)
Trial: 3323852
Drug: Sequential oestrogen/progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential oestrogen/progestogen therapy (4 mg, 2 mg, and 1 mg 17 beta‐oestradiol combined with 1 mg norethisterone acetate)
Trial: 26777721
Drug: Real-time daily
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time daily patient feedback to providers along with provider coaching and revisits of patients not reporting optimal satisfaction with their care.
Trial: 25178594
Drug: Azithromycin at
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin at a dose of 10mg/kg/day for 7 days
Trial: 25178594
Drug: Cefixime at
RxNorm normalized name: Cefixime
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefixime at a dose of 20mg/kg/day in two divided doses for 14 days
Trial: 20463186
Drug: RTX 2
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX 2 x 500 mg